Phoebe King, MD
Pulmonary Disease · Sandy, UTNPI 1760630321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 37.4% of the total. Reporting peaked in 2022 at $714 and has fallen 95.9% since, to $29 in 2025.
Across 122 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$800
- Mylan Specialty L.p.$394
- Actelion Pharmaceuticals US, Inc.$176
- Abiomed$147
- Grifols USA, LLC$104
- AstraZeneca$86
- plus $431 from 16 others
What the payments were for
- Food & beverage$2,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $800 |
| Mylan Specialty L.p. | 17 | $394 |
| Actelion Pharmaceuticals US, Inc. | 11 | $176 |
| Abiomed | 1 | $147 |
| Grifols USA, LLC | 4 | $104 |
| AstraZeneca | 5 | $86 |
| Boehringer Ingelheim | 4 | $61 |
| Philips North America LLC | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Verona Pharma, Inc. | 1 | $29 |
| Olympus America Inc. | 1 | $28 |
| Electromed, Inc. | 2 | $25 |
| Sanofi | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Gilead | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$147
How this compares
$2,136 in reported general payments places this provider in the 65th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $163,133 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $61,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $59,924 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $34,925 |
| Spiriva RespimatTiotropium Bromide | 47 | $24,149 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $23,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $14,380 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $14,037 |
| BreynaBudesonide/Formoterol Fumarate | 45 | $10,348 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,748 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,599 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,551 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,115 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $2,579 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $61 | $228,954123 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $800 | $102,582149 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $86 | $75,986121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Sandy
- Mary ScholandSalt Lake City$325K
- Talaat Al ShuqairatSalem$248K
- Charles IvesterSouth Ogden$99K
- Chakravarthy ReddySalt Lake City$82K
- Timothy LeclairMurray$74K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Sunny PanditaMurray$25K
- Meghan CirulisMurray$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.